When a patient is diagnosed with stage 3 melanoma, their options have, until now, been very limited.  Most patients were put on a ‘watch and wait’ scheme and this has never sat well with the patient community.

We are delighted that National Institute for Health and Care Excellence (NICE) has issued  a Final Appraisal Document (FAD) recommending the reimbursement within the Cancer Drugs Fund (CDF) of the immunotherapy, Opdivo® (nivolumab), as adjuvant treatment after surgery, to potentially keep the cancer from returning, for melanoma patients in England.

It will be available immediately via the Cancer Drugs Fund and could benefit as many as 1480 patients every year in the UK.  

 

Read more